ClinicaliQ Trial Snapshot
- Rebalancing the Fat Content of the Heart and Muscles — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT07065383.
- Sponsor: University of Aberdeen.
Verify eligibility, endpoints and current status on the original source registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Traditional diabetes therapies focus on improving blood sugar control. However, many studies show that this may not be enough. New treatments focusing on weight loss have heralded better results. One of these treatments is Semaglutide and the investigators wish to examine its effects further in this study. The investigators propose to investigate what happens to the fat inside the heart and the leg muscles.
Eligibility Snapshot
- : * Patients with a confirmed diagnosis of type 2 diabetes established in the previous 10 years between the ages of 20 and 75 * HbA1c ≥ 53 mmol/mol (7%) typically on diet and/or metformin/sulphonylureas (and/or sodium-glucose cotransporter-2 inhibitors, Dipeptidyl peptidase 4 inhibitors, thiazolidinediones, but not on insulin) * Patients who do not meet the WHO recommendations on physical activity (≤150 minutes per week) of moderate-vigorous physical activity (MVPA) * Patients who have a BMI of ≥27 but with a body weight of less than 140kgs due to limitations of the scanner table weight limit * Current or recent (within 3 months) eGFR >30 mL/min/1.73m2) * Able to understand written and spoken English
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.